CAM
LAB icon

Cresset Asset Management’s Standard BioTools LAB Stock Holding History

Cresset Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,902
Closed -$26.9K – 1626
2025
Q1 		$26.9K Sell
24,902
-3,969
-14% -$5.57K ﹤0.01% 1680
2024
Q4 		$50.5K Sell
28,871
-5,212
-15% -$9.71K ﹤0.01% 1666
2024
Q3 		$65.8K Buy
34,083
+23,225
+214% +$45.5K ﹤0.01% 2076
2024
Q2 		$19.2K Buy
+10,858
New +$26.5K ﹤0.01% 2051
2019
Q2 		– Sell
-810
Closed -$11K – 1118
2019
Q1 		$11K Buy
810
+115
+17% +$1.21K ﹤0.01% 1151
2018
Q4 		$6K Buy
+695
New +$5.41K ﹤0.01% 978

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cresset Asset Management's LAB Position: Q2 2025 in Review

Cresset Asset Management sold out of Standard BioTools (LAB) in Q2 2025, closing a stake of 24,902 shares — an estimated $26.9K sold.

Cresset Asset Management first reported a position in LAB in Q4 2018 and held it in 6 quarters. The position peaked at $65.8K in Q3 2024. 160 funds tracked by Wall St. Rank hold LAB as of Q2 2025.

  • Cresset Asset Management reported no remaining Standard BioTools position as of Q2 2025 after selling out during the quarter.
  • Cresset Asset Management sold 24,902 Standard BioTools shares in Q2 2025, an estimated $26.9K.
  • Cresset Asset Management first reported a position in Standard BioTools in Q4 2018 and held it in 6 quarters.
  • Cresset Asset Management's Standard BioTools position peaked at $65.8K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2025.

Based on Cresset Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.